MTNB (Matinas BioPharma Holdings) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MTNB Matinas BioPharma Holdings Inc MTNB
30 GF Score
Price $0.31
! 3 Warning Signs
View Full Analysis

What is Matinas BioPharma Holdings 5-Year Yield-on-Cost %?

Matinas BioPharma Holdings MTNB -9.78% 30 5-Year Yield-on-Cost % is 0.00 as of Jul. 20, 2026. GuruFocus rates MTNB with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 153 Biotechnology companies, Matinas BioPharma Holdings ranks worse than 653594.12% on this metric.

Matinas BioPharma Holdings's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Matinas BioPharma Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:



MTNB's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.69
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Matinas BioPharma Holdings  (AMEX:MTNB) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Matinas BioPharma Holdings 5-Year Yield-on-Cost % Related Terms

MTNB vs SXTP, ARTL, GLMD: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Matinas BioPharma Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Matinas BioPharma Holdings 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's 5-Year Yield-on-Cost % falls into.


MTNB
30GF Score
Matinas BioPharma Holdings Inc MTNB
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Matinas BioPharma Holdings 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Matinas BioPharma Holdings is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Matinas BioPharma Holdings (MTNB) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 20, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Matinas BioPharma Holdings and its competitors. According to the industry distribution chart, Matinas BioPharma Holdings ranks #999999 out of 153 companies in the Biotechnology industry.
Is Matinas BioPharma Holdings' 5-Year Yield-on-Cost % too high?
Matinas BioPharma Holdings' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Matinas BioPharma Holdings ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Matinas BioPharma Holdings has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Matinas BioPharma Holdings' 5-Year Yield-on-Cost % compare to SXTP and ARTL?
According to the Biotechnology industry distribution chart, Matinas BioPharma Holdings ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Matinas BioPharma Holdings in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.69, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Matinas BioPharma Holdings and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Matinas BioPharma Holdings's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Matinas BioPharma Holdings stock overvalued right now?
Matinas BioPharma Holdings (MTNB) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Matinas BioPharma Holdings' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Matinas BioPharma Holdings (MTNB), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Matinas BioPharma Holdings Business Description

Address 1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
30GF Score

Get the complete analysis for MTNB

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.31
Price